Latest Conference Articles

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.

Mathew Maurer, MD, discusses the results of the phase 3 REVEAL study, which highlighted this novel scanning technology’s capacity for identifying amyloidosis early.

George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.

Quin Denfeld, PhD, discusses her findings from the BIOMES-HF study, indicating worsening symptoms in patients with HF over time.

Ronnie Fass, MD, discusses phase 3 TRIUMpH-NERD data showing tegoprazan increased heartburn-free and regurgitation-free days vs placebo in NERD.

Tina Bhutani, MD, MAS, discusses 3-year VALUE data on risankizumab in high-impact psoriasis and why biologics belong earlier in moderate disease.

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.

Nicholas Shaheen, MD, MPH, discusses DETECT-ME data showing a capsule-sponge methylation test detected Barrett’s esophagus with 90% sensitivity.

Anastasia Shchendrygina, MD, PhD, discusses her recent study evaluating colchicine’s effects on major biomarkers of HFpEF and its pathophysiology.

GI health care use still fell among patients who had already tried another IBS-C drug, per a real world ACG 2026 analysis.

A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.

Victoria P. Werth, MD, and François Chasset, MD, PhD, discuss 52-week AMETHYST Part A data showing litifilimab responses continued to rise.

James Januzzi, MD, discusses the recently released guideline update and how it should change clinicians’ priorities in addressing and preempting HFpEF.

A real world analysis of 470 patients presented at ACG 2026 found median GI visits fell from 4.5 to 3.0 in the year after initiation

James Januzzi, MD, discusses his post-hoc analysis of the ATTRibute-CM study, revealing a potential predictive ratio between these 2 measurements.

Aasma Shaukat, MD, MPH, discusses an updated SimpleScreen CRC blood test with 18.2% sensitivity for advanced precancerous lesions, up from 13.7%.

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

Evan Dellon, MD, discusses phase 3 CROSSING data in which tezepelumab improved histology, dysphagia, and endoscopic findings vs placebo in EoE.

In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.

Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.

Martin Maron, MD, discusses the results of his responder analysis of the trial, presented at HFSA 2026, and the implications for aficamten’s path towards approval.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.